Mdivi-1 and Nutlin-3 Combination for Ophthalmic Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, ischemic optic neuropathies, hereditary optic neuropathies, and retinal artery/vein occlusions do not effectively inhibit apoptosis and provide neuroprotection, as they either induce apoptosis or lack sufficient neuroprotective effects.
Innovation Solution
The combination of mdivi-1 and nutlin-3, administered topically or intravitreally, blocks the Bax/Bak and Drpl interaction on mitochondria, inhibiting apoptosis and providing neuroprotection by inhibiting the apoptosis pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for glaucoma and optic neuropathies, then intraocular pressure may be reduced, but apoptosis is not effectively inhibited and neuroprotection is insufficient
Solution Approach 1:
The treatment approach is segmented into two distinct mechanistic pathways: one targeting Bax/Bak apoptosis activation and another targeting Drp1 mitochondrial fission. This segmentation allows each compound to address specific apoptotic mechanisms independently, achieving comprehensive apoptosis inhibition without the harmful effects of single-agent therapies.
Solution Approach 2:
The invention uses a composite therapeutic approach combining mdivi-1 (mitochondrial fission inhibitor) and nutlin-3 (Bax/Bak interaction inhibitor). This composite strategy targets multiple points in the apoptosis pathway simultaneously, creating a synergistic effect that enhances neuroprotection while preventing the harmful apoptosis induction that occurs with conventional monotherapies.
2Reliability
If single-agent therapies are used, then treatment simplicity is maintained, but apoptosis inhibition and neuroprotection are insufficient
Solution Approach 1:
The invention merges two anti-apoptotic mechanisms into a single combined therapy regimen. Mdivi-1 and nutlin-3 are administered together to simultaneously block mitochondrial fission and Bax/Bak interaction, achieving superior apoptosis inhibition that neither agent can achieve alone, while maintaining a relatively simple topical or intravitreal administration route.
Solution Approach 2:
The invention changes the therapeutic parameters by targeting specific molecular interactions (Bax/Bak and Drp1) rather than using broad-spectrum conventional treatments. This parameter-specific approach allows for precise apoptosis inhibition through molecular mechanism targeting, improving efficacy while the combined agent strategy manages the complexity of the treatment regimen.
3Productivity
If treatments that induce apoptosis are used, then cell turnover is promoted, but neuroprotection is compromised and ophthalmic diseases worsen
Solution Approach 1:
The invention inverts the conventional approach by using apoptosis inhibitors rather than apoptosis inducers. Instead of promoting cell death and turnover as with traditional chemotherapeutic or anti-proliferative agents, mdivi-1 and nutlin-3 block the apoptosis pathway to preserve neuronal cells, achieving neuroprotection while preventing the harmful cell loss that would otherwise occur.
Data Source
AI summary
Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.